Related Experiment Video

Updated: Jun 21, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Natriuretic peptides in the diagnosis and management of chronic heart failure

Guido Boerrigter1, Lisa C Costello-Boerrigter, John C Burnett

  • 1Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. boerrigter.guido@mayo.edu

Heart Failure Clinics
|July 28, 2009
PubMed

Insights

The BNP system aids cardiovascular disease diagnosis and prognosis. New molecular forms and genetic factors like rs198389 enhance its biomarker potential for heart failure (HF) and beyond.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Genetics

Background:

  • The B-type natriuretic peptide (BNP) system is crucial for diagnosing cardiovascular diseases.
  • BNP levels offer prognostic insights for heart failure (HF) patients, the general population, and other patient groups.
  • Temporal changes in BNP levels also provide prognostic information, leading to research in BNP-guided treatment strategies.

Purpose of the Study:

  • To explore the diagnostic and prognostic utility of the BNP system in cardiovascular disease.
  • To investigate emerging insights into the biology of the BNP system through the identification of circulating molecular forms.
  • To assess the impact of genetic variations, such as the rs198389 polymorphism, on BNP system biomarkers.

Main Methods:

  • Analysis of circulating BNP system components.
  • Identification and characterization of novel molecular forms of BNP.
  • Evaluation of the influence of the rs198389 single nucleotide polymorphism on BNP levels.
  • Correlation of BNP levels and molecular forms with cardiovascular disease diagnosis and prognosis.

Main Results:

  • Circulating BNP system levels are valuable for diagnosing cardiovascular disease.
  • BNP provides prognostic information for HF patients and the general population.
  • Emerging molecular forms of BNP offer new biological insights.
  • The rs198389 polymorphism influences BNP levels, potentially refining biomarker use.

Conclusions:

  • The BNP system is a versatile biomarker for cardiovascular disease diagnosis and prognosis.
  • Understanding BNP's molecular forms enhances its biological and clinical relevance.
  • Genetic factors like rs198389 can modulate BNP levels, aiding in personalized biomarker application.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.